Edgestream Partners L.P. Cuts Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Edgestream Partners cut its Johnson & Johnson stake by 39.3% in the first quarter, selling 7,775 shares and retaining 11,991 shares valued at approximately $2.93 million. Institutional investors collectively own 69.55% of JNJ.
• Johnson & Johnson exceeded quarterly expectations, reporting $2.90 in adjusted EPS on $25.31 billion in revenue, with year-over-year revenue growth of 6.6%. Analysts remain bullish, assigning the stock a “Moderate Buy” consensus rating and an average price target of $266.39.
• The company will pay a quarterly dividend of $1.34 per share on September 8, equal to a 2.1% annualized yield. Growth prospects include oncology investments and regulatory progress, while a proposed $5.5 billion talc settlement remains a key risk.

Edgestream Partners L.P. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 39.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,991 shares of the company's stock after selling 7,775 shares during the quarter. Edgestream Partners L.P.'s holdings in Johnson & Johnson were worth $2,931,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock worth $49,740,362,000 after acquiring an additional 3,731,074 shares during the last quarter. State Street Corp lifted its position in Johnson & Johnson by 1.3% in the fourth quarter. State Street Corp now owns 133,869,843 shares of the company's stock valued at $27,704,364,000 after purchasing an additional 1,663,782 shares during the last quarter. Auto Owners Insurance Co boosted its stake in shares of Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock valued at $1,436,633,000 after purchasing an additional 69,108,368 shares during the period. Geode Capital Management LLC boosted its stake in shares of Johnson & Johnson by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company's stock valued at $11,967,947,000 after purchasing an additional 1,738,292 shares during the period. Finally, Norges Bank bought a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $6,924,523,000. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. Daiwa Securities Group increased their price target on shares of Johnson & Johnson from $237.00 to $246.00 and gave the company an "outperform" rating in a research report on Thursday, April 16th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a report on Thursday, July 16th. Leerink Partners raised shares of Johnson & Johnson from a "market perform" rating to an "outperform" rating and set a $265.00 price objective for the company in a research note on Wednesday, May 13th. Finally, The Goldman Sachs Group reiterated a "buy" rating and set a $282.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $266.39.

Johnson & Johnson Price Performance

JNJ opened at $256.51 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The stock has a market capitalization of $618.18 billion, a PE ratio of 29.72, a price-to-earnings-growth ratio of 2.43 and a beta of 0.24. The stock's 50 day moving average price is $245.85 and its 200-day moving average price is $238.31. Johnson & Johnson has a 52-week low of $164.23 and a 52-week high of $274.90.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm's revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities research analysts predict that Johnson & Johnson will post 11.69 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio (DPR) is currently 62.11%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analysts remain moderately bullish: JNJ’s median analyst price target is about $263, with several targets above that level, including Citigroup’s $298 target. Argus Research also issued a Buy rating, while Erste Group raised its 2026 EPS forecast to $11.68, close to the $11.69 consensus. Is Wall Street Bullish or Bearish on Johnson & Johnson Stock?
• Positive Sentiment: Oncology and immunology expansion strengthens the growth pipeline: J&J completed its $1 billion acquisition of Firefly Bio, adding a degrader antibody-conjugate platform targeting difficult solid tumors, including KRAS-driven cancers. Johnson & Johnson Completes Acquisition of Firefly Bio
• Positive Sentiment: Promising regulatory and shareholder-return news: The FDA granted Priority Review to subcutaneous RYBREVANT FASPRO for advanced head and neck cancer, potentially expanding a key oncology franchise. JNJ also increased its dividend for the 64th consecutive year and is pursuing a long-term $100 billion revenue goal. RYBREVANT FASPRO Receives FDA Priority Review
• Neutral Sentiment: In-vivo CAR-T investment adds potential but carries execution risk: JNJ will make up to $785 million in initial payments to Sail Biomedicines and has an option to acquire it for $2.58 billion. The technology could create new autoimmune and oncology treatments, but commercialization is still uncertain. J&J Ventures Further Into In Vivo CAR-T
• Negative Sentiment: The $5.5 billion talc settlement weighs on sentiment: The proposed agreement would resolve roughly 76,000 ovarian-cancer claims, subject to 95% claimant participation. Although it could reduce litigation uncertainty, investors are focused on the substantial cash obligation, including up to $3 billion in 2027, and execution risk. Johnson & Johnson to Pay $5.5 Billion to Resolve Talc Litigation

Insider Activity

In other news, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Kathryn E. Wengel sold 10,000 shares of the business's stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.